HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francesc García-Pallarols Selected Research

VAP-cyclo protocol

3/2011Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francesc García-Pallarols Research Topics

Disease

2Lymphoma (Lymphomas)
06/2015 - 03/2011
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
06/2019
1Cardiotoxicity
06/2019
1Disease Progression
03/2019
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2017
1Essential Thrombocythemia
11/2012
1Polycythemia Vera
11/2012

Drug/Important Bio-Agent (IBA)

2AnthracyclinesIBA
06/2019 - 06/2015
2Rituximab (Mabthera)FDA Link
01/2017 - 03/2011
1pro-brain natriuretic peptide (1-76)IBA
06/2019
1Natriuretic PeptidesIBA
06/2019
1Hemoglobins (Hemoglobin)IBA
11/2012
1Doxorubicin (Adriamycin)FDA LinkGeneric
03/2011
1liposomal doxorubicin (Doxil)FDA Link
03/2011

Therapy/Procedure

2Drug Therapy (Chemotherapy)
06/2015 - 03/2011
1Therapeutics
03/2019
1VAP-cyclo protocol
03/2011